Background and Purpose-Acute intraprocedural thrombus formation complicating endovascular cerebral aneurysm treatment is often treated with intra-arterial or intravenous administration of thrombolytic agents or glycoprotein IIb/IIIa (GpIIb/IIIa) inhibitors. We sought to evaluate the morbidity and mortality associated with such treatments using a large multihospital database. Methods-Using the Premier Perspective Database, we examined outcomes for patients receiving endovascular coiling for ruptured and unruptured aneurysms requiring rescue therapy, defined as treatment with GpIIb/IIIa inhibitors and fibrinolytic therapy. We compared discharge status, length of stay, and complication rates across 3 groups: (1) patients receiving GpIIb/IIIa inhibitors only, (2) patients receiving fibrinolytic therapy only, and (3) 
P eriprocedural thromboembolic complications from endovascular treatment of intracranial aneurysms are estimated to occur in ≈2% to 15% of patients. 1 Aggressive treatment of acute intraprocedural thrombus formation with intra-arterial or intravenous administration of fibrinolytics or glycoprotein IIb/IIIa (GpIIb/IIIa) inhibitors has become a standard treatment for these complications. Recanalization of the treated artery is usually essential to avoid permanent neurological deficit. Many studies have demonstrated benefit from the intraprocedural administration of GpIIb/IIIa inhibitors and thrombolytic agents during endovascular treatment of intracranial aneurysms. However, the real-world outcomes of patients requiring such treatments are not well known. Using a large multihospital database, we sought to determine the periprocedural morbidity and mortality of patients requiring rescue therapy (ie, intraprocedural administration of GpIIb/ IIIa inhibitors or thrombolytic agents) during endovascular treatment of intracranial aneurysms.
Methods

Study Population and Data Retrieval
The Premier Perspective database is a voluntary, fee-supported collection of data developed by Premier, Inc. to assess quality and resource use. As of 2011, the Perspective database consisted of ≈15% of hospitalizations nationwide and represented >600 US hospitals. Detailed information of a patient's hospitalization, including patient demographics, hospital information, diagnoses, procedures, discharge status, and all billed items are recorded. 
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Patients with ruptured and unruptured aneurysm who received rescue therapy were identified using billing records. GpIIb/IIIa therapy or fibrinolytic recue therapy was included only if they were administered on the day of or the day after the coiling procedure. Antiplatelet rescue therapy was defined as administration of Abciximab (ReoPro), Eptifibatide (Integrillin), or Tirofiban (Aggrastat). Fibrinolytic rescue therapy was defined as administration of Alteplase (Activase), Reteplase (Retavase), Tenecteplase (Tnkase), or Urokinase (Abbokinase).
We compared demographics and outcomes from patients with unruptured aneurysm and patients with subarachnoid hemorrhage separately. For each patient population, we compared outcomes across 3 groups: (1) patients receiving GpIIb/IIIa inhibitors only, (2) patients receiving fibrinolytic therapy only, and (3) patients receiving both GpIIb/IIIa inhibitors and fibrinolytics. The following demographic variables were compared: (1) age, (2) sex, (3) hospital location (urban versus rural), (4) hospital teaching status, and (5) stent-assisted coiling rates. The following outcomes were compared: (1) discharge status (mortality, discharge to institution other than home, discharge to home/home care); (2) length of stay; and rates of (3) aphasia, (4) hemiparesis, (5) postoperative neurological complications, and (6) ventriculostomy. Discharge to institutions other than home was used as an indicator of morbidity. Hemorrhage rates were compared for the unruptured aneurysm group only.
Statistics
Data were extracted from the Perspective database using SAS (SAS, version 9.3; SAS Institute, Cary, NC) and analyzed using JMP (version 9, SAS Institute, Cary, NC 
Results
Unruptured Aneurysm Group
A total of 3627 patients in the Premier Perspective database received endovascular therapy for treatment of unruptured aneurysm. Of which, 254 patients (7.0%) received rescue therapy with GpIIb/IIIa inhibitor and thrombolytic agents; 202 patients (5.6%) received GpIIb/ IIIa inhibitor rescue therapy; 24 patients (0.7%) received fibrinolytic therapy; and 28 patients (0.8%) received both fibrinolytic and GpIIb/IIIa inhibitor rescue therapy. The demographic characteristics of these patients are summarized in Table 1 .
Patients receiving GpIIbIIIa inhibitors had significantly better outcomes compared with the fibrinolytic group. GpIIbIIIa inhibitor patients had significantly higher rates of discharge to home/home care compared with patients receiving fibrinolytic therapy (90.6%, 183/202 versus 58.3%, 14/24, respectively; P<0.0001). There was a trend for GpIIbIIIa inhibitor patients to have higher rates of discharge to home/home care facilities compared with the combination therapy group (90.6%, 183/202 versus 78.6%, 22/28, respectively; P=0.06). GpIIbIIIa inhibitor patients had decreased rates of aphasia compared with the fibrinolytic therapy group (1.5%, 3/202 versus 8.3%, 2/24, respectively; P=0.03). Compared with patients receiving combination therapy, patients receiving GpIIbIIIa inhibitors had decreased rates of hemorrhage (2.0%, 4/202 versus 10.7%, 3/28, respectively; P=0.01). These data are summarized in Table 2 . 
Discussion
Using a large administrative database, we demonstrated that ≈7% to 8% of patients who underwent endovascular treatment of unruptured or ruptured intracranial aneurysms received rescue therapy with intraprocedural administration of either GpIIb/IIIa inhibitor agents or thrombolytic agents. GpIIb/IIIa inhibitors were used at much higher rates than thrombolytics.
Notably, outcomes for patients with both unruptured and ruptured aneurysm, on the basis of numerous outcomes, including discharge status, aphasia, and other complications, were significantly better for patients receiving GpIIb/IIIa inhibitors than those treated with fibrinolytic agents. These data should prompt practitioners to avoid fibrinolytics in place of GpIIb/ IIIa agents for rescue therapy during coil embolization of both ruptured and unruptured aneurysms.
In most case series, the rate of rescue therapy for thromboembolic complications ranges between 5% and 10%. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] The infarction rate among patients receiving rescue therapy ranges between 10% and 40% with higher rates generally seen in studies with postoperative MR imaging [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] ( Table 5 ). In a series of 477 patients with 515 intracranial aneurysms, Ries et al 1 reported that 48 patients (10%) had thromboembolic events; 42 of these patients received rescue therapy with GpIIbIIIa inhibitors, and 1 patient received rescue therapy with recombinant tissue plasminogen activator. Of the patients who did not receive rescue therapy, 3/5 had infarcts, whereas 31% of patients receiving GpIIbIIIa inhibitor rescue therapy had infarction on computed tomography. Linfante et al 10 demonstrated that ≈10% of patients undergoing endovascular embolization of intracranial aneurysms required intra-arterial GpIIbIIIa inhibitor rescue therapy with an infarct and hemorrhage rate of 0%. Many previous studies that have demonstrated high-infarct rates on postoperative imaging also highlight the fact that many of these infarcts are clinically silent. 1, 2, 9 We cannot evaluate infarct rates or success of recanalization with thrombolytic agents versus GpIIb/IIIa inhibitors in this study, but better outcomes suggest that GpIIb/IIIa inhibitors are a better option for rescue therapy. 15, 16 
Stroke
May 2013
The use of GpIIb/IIIa inhibitors in patients with ruptured aneurysms has been reported to be relatively safe with most series reporting intracranial hemorrhage rates of <10%. [1] [2] [3] [7] [8] [9] [10] 12 Aviv et al 3 reported 13 patients with ruptured aneurysm treated with abciximab rescue therapy and only 1 hemorrhagic complication. Aggour et al 2 included 11 patients with ruptured aneurysm in their abciximab rescue series without hemorrhagic complication. Park et al 12 reported hemorrhagic complications in 3 of 16 patients with ruptured cerebral aneurysms treated with abciximab rescue therapy. On the other hand, the literature has shown that rescue therapy with thrombolytic agents in patients with ruptured aneurysms is associated with a very high mortality. In a series reported by Cronqvist et al 17 of 19 patients undergoing rescue therapy with urokinase, 3 had intracranial bleeding complications. In the International Subarachnoid Aneurysm Trial (ISAT), 5 patients had thromboembolic complications treated with thrombolytic agents, and all 5 died from rebleeding of their ruptured aneurysms. 18 Catastrophic hemorrhage has also been reported with rescue using thrombolytic agents in setting of an unruptured aneurysm. 19 There are few reports on rescue therapy with thrombolytic agents, [15] [16] [17] [18] [19] perhaps because their use has been largely replaced by GpIIbIIIa inhibitors. Despite these past reports, our study shows that thrombolytic agents continue to be used. Our data confirm the higher risk of morbidity and mortality of thrombolytic agents relative to GpIIbIIIa inhibitors, and might help to discourage continued use of thrombolytic agents for rescue therapy, especially in the setting of subarachnoid hemorrhage.
Limitations
Our study has limitations. Using this database, we are unable to determine whether some patients had intraprocedural thrombus formation and did not receive rescue therapy. Thus, we are unable to compare outcomes between treatment and nontreatment groups. Furthermore, we are unable to determine whether patients with subarachnoid hemorrhage had further bleeding as a result of rescue therapy. Thus, the bleeding rate can only be obtained for patients presenting with unruptured aneurysm. This database does not offer any data on presenting condition and aneurysm geometric features (aspect and dometo-neck ratio), size, or location. Thus, we are unable to correlate our outcomes with the anatomic features of the treated aneurysm. We are unable to assess whether the rescue agent was given by intra-arterial or intravenous route. Some patients may have received GpIIbIIIa inhibitors for prophylaxis of thromboembolism, but this should be relatively uncommon, as it is not standard practice and would be contraindicated with subarachnoid hemorrhage. Coding inaccuracies can affect the accuracy of any administrative database, including the Premier Perspective database.
Conclusions
Using a large administrative database, we demonstrated an intraprocedural rescue therapy rate of ≈7% to 8% for endovascular coiling patients with unruptured and ruptured intracranial aneurysms. Rescue therapy with thrombolytic agents resulted in significantly more morbidity and mortality than rescue therapy with GpIIbIIIa inhibitors. 
